Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Posternak

Showing results (51-60 of 149) with videos related to

Pageof 15
Sort By:
Advances in Cyclic Nucleotide Research|January 1, 1972
A study of the bioloical activity and resistance to phosphodiesterase of some derivatives and analogues of cyclic AMPG Cehovic, T Posternak, E Charollais
Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences. Serie D: Sciences Naturelles|January 25, 1971
[Preparation of new derivatives of cAMP (substituted in position C-8 and C-2) and study of their action on the release of growth hormone]T Posternak, I Marcus, G Cehovic
The American Journal of Psychiatry|July 5, 2005
Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trialMark Zimmerman, Iwona Chelminski, Michael A Posternak
Dialogues in Clinical Neuroscience|January 28, 2009
Toward achieving optimal response: understanding and managing antidepressant side effectsKaren Kelly, Michael Posternak, Jonathan E Alpert
Biochimica Et Biophysica Acta|April 21, 1970
[Inositol transport in Schizosaccharomyces pombe]J P Cheneval, J Deshusses, T Posternak
Essential Psychopharmacology|December 23, 2004
Generalizability of antidepressant efficacy trialsMark Zimmerman, Michael A Posternak, Iwona Chelminski
The Journal of Nervous and Mental Disease|February 11, 2004
Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples includedMark Zimmerman, Iwona Chelminski, Michael A Posternak
The Journal of Clinical Psychiatry|March 9, 2004
Defining remission on the Montgomery-Asberg depression rating scaleMark Zimmerman, Michael A Posternak, Iwona Chelminski
Journal of Clinical Psychopharmacology|November 28, 2002
Symptom severity and exclusion from antidepressant efficacy trialsMark Zimmerman, Michael A Posternak, Iwona Chelminski
Journal De Physiologie|January 1, 1970
[Narcotic power of nitrogen protoxide examined on various nervous structures]M Dolivo, C Foroglou, J M Posternak
Pageof 15

Showing results (51-60 of 149) with videos related to

Sort By:
Pageof 15
Advances in Cyclic Nucleotide Research|January 1, 1972
A study of the bioloical activity and resistance to phosphodiesterase of some derivatives and analogues of cyclic AMPG Cehovic, T Posternak, E Charollais
Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences. Serie D: Sciences Naturelles|January 25, 1971
[Preparation of new derivatives of cAMP (substituted in position C-8 and C-2) and study of their action on the release of growth hormone]T Posternak, I Marcus, G Cehovic
The American Journal of Psychiatry|July 5, 2005
Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trialMark Zimmerman, Iwona Chelminski, Michael A Posternak
Dialogues in Clinical Neuroscience|January 28, 2009
Toward achieving optimal response: understanding and managing antidepressant side effectsKaren Kelly, Michael Posternak, Jonathan E Alpert
Biochimica Et Biophysica Acta|April 21, 1970
[Inositol transport in Schizosaccharomyces pombe]J P Cheneval, J Deshusses, T Posternak
Essential Psychopharmacology|December 23, 2004
Generalizability of antidepressant efficacy trialsMark Zimmerman, Michael A Posternak, Iwona Chelminski
The Journal of Nervous and Mental Disease|February 11, 2004
Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples includedMark Zimmerman, Iwona Chelminski, Michael A Posternak
The Journal of Clinical Psychiatry|March 9, 2004
Defining remission on the Montgomery-Asberg depression rating scaleMark Zimmerman, Michael A Posternak, Iwona Chelminski
Journal of Clinical Psychopharmacology|November 28, 2002
Symptom severity and exclusion from antidepressant efficacy trialsMark Zimmerman, Michael A Posternak, Iwona Chelminski
Journal De Physiologie|January 1, 1970
[Narcotic power of nitrogen protoxide examined on various nervous structures]M Dolivo, C Foroglou, J M Posternak
Pageof 15